कंपनी का अवलोकन
Lyra Therapeutics, Inc. operates as a clinical-stage biotechnology entity dedicated to the development and commercialization of anti-inflammatory therapies specifically designed to treat patients suffering from chronic rhinosinusitis. The company's proprietary technology is engineered to facilitate the direct delivery of medicinal compounds directly to the affected tissue, ensuring sustained therapeutic effects for patients with this chronic condition. This organization functions within the broader Healthcare sector, with a specific focus on the Biotechnology industry, positioning it as a specialized player in the medical research and drug development landscape. With a market capitalization of $870,402 and annual revenue of $398,000, the company represents a micro-cap entity with a very small operational footprint. These valuation figures and revenue levels indicate that Lyra Therapeutics is in an early-stage development phase, typical for clinical-stage biotechnology firms that have not yet achieved significant commercial scale or profitability.
वित्तीय स्वास्थ्य
The company reported revenue of $398,000 over the trailing twelve months, yet it recorded a net income of $-28,919,000 and an EBITDA of $-29,094,000, highlighting a significant disparity between top-line generation and bottom-line performance. The substantial gap between the minimal revenue and the massive net loss reveals a cost structure heavily weighted toward research and development expenses, which are characteristic of clinical-stage biotechnology companies before product approval. Free cash flow stands at $-17,529,624, indicating that the company is consuming cash reserves to fund its operations and development pipeline rather than generating surplus liquidity. This negative cash flow suggests that the company relies on external financing or existing cash balances to sustain its financial flexibility during the pre-revenue or early commercialization stages. The gross margin is reported at -152.8%, while the operating margin reaches -98,728.6% and the profit margin is 0.0%, collectively indicating that the company is burning capital to develop its technology without yet achieving a sustainable revenue model. Total cash on hand is $15.89M, which is insufficient to cover total debt of $30.26M, resulting in a negative equity position that renders the debt-to-equity ratio N/A. Despite the negative equity, the current ratio is 1.71, which technically indicates that the company holds sufficient current assets to cover its current liabilities, though this metric does not account for the long-term debt burden. The return on equity is -6595.0% and the return on assets is -36.1%, metrics that reveal that management has not yet generated positive returns on the capital invested in the company.
मूल्यांकन आकलन
Lyra Therapeutics does not have a trailing P/E ratio available due to its lack of earnings, while the forward P/E is listed at -0.50, implying that the market is pricing in expectations of future losses rather than established profitability. The price-to-book ratio is -0.19, indicating that the market values the company at a fraction of its book value, which is common for distressed or pre-profitability biotechnology firms. The price-to-sales ratio stands at 2.19 and the EV/EBITDA is -0.53, suggesting that investors are valuing the company primarily based on its potential for future revenue generation rather than current earnings power. The stock has traded between a 52-week high of $37.50 and a 52-week low of $0.31, placing the current market price significantly below the peak valuation and reflecting high volatility inherent in small-cap biotech stocks. The beta value is 0.30, indicating that the stock's price volatility is substantially lower than the broader market, likely due to the specific niche nature of its anti-inflammatory therapy focus and the limited liquidity of its shares.
Growth & Income
The company experienced a revenue growth rate of -96.7% year-over-year, while earnings growth is N/A due to the absence of prior period profits for comparison. The decline in revenue implies that the company is still in the experimental or early commercialization phase where sales figures are not yet stable or growing. Since the company is not a dividend payer, there is no dividend yield or payout ratio to assess, meaning all available cash is reinvested into research, development, and operational costs rather than distributed to shareholders. The overall growth and income profile characterizes Lyra Therapeutics as a high-risk, high-potential venture that currently generates negative returns and negative cash flow while attempting to bring specialized therapies to market.